Research

The Hayashi Lab is dedicated to improving the treatment for pediatric sarcoma patients. We utilize in vitro and in vivo preclinical models and patient-derived samples to discover novel ways to target sarcoma metastasis, and use a wide variety of techniques to develop novel blood-based biomarkers that can lead to more efficient and effective therapy.

Liquid Biopsies

Liquid biopsies, utilize analysis of patient body fluids, such as blood, CSF, and urine, and can be used to identify genetic phenotypes of tumors, risk stratify patients, detect minimal residual disease, and search for novel therapeutic targets.

Prospective Liquid Biopsy validation study

MCC20320: Blood based biomarkers for minimal residual disease detection in pediatric sarcomas

This multi-center prospective clinical trial sponsored by the National Pediatric Cancer Foundation aims to prospectively validate the use of ctDNA and CTC to detect recurrence in newly diagnosed patients with Ewing sarcoma, osteosarcoma, and rhabdomyosarcomas treated on standard treatment regimens.

Clinical Trial Correlative studies (completed, and ongoing)

SARC037 A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging
PBTC-055 Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults
SALA-002, MCC19365 Phase 1 Trial of the LSD1 Inhibitor SP-2577 in Patients with Relapsed or Refractory Ewing Sarcoma
MCC18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
MCC20339 Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma
MCC21704 A Multi-Institution Study of TGFβ imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue Sarcomas: The TiNKS Trial
MCC23221 Evaluation of Digoxin for Relapsed/Refractory non-WNT, non-SHH Medulloblastoma
MCC23281 Metastatic Ewing’s Trial Testing Schedule Enhancement to Improve Outcomes

Preclinical Studies

Our lab uses various in vitro cell lines and patient derived xenograft models, to discover novel insights into the biology of sarcoma metastasis, and to test novel therapeutics.